Statin Therapy Significantly Reduces Risk of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter Defibrillator
| Autor: | Ankit Rathod, Palaniappan Manickam, Sony Jacob, Apurva Badheka, Luis Afonso, Rajeev Aravindhakshan |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Risk
medicine.medical_specialty medicine.medical_treatment Myocardial Ischemia Cardioversion Ventricular tachycardia Cohort Studies Recurrence Risk Factors Internal medicine medicine Humans Pharmacology (medical) Prospective cohort study Pharmacology Ischemic cardiomyopathy business.industry Incidence General Medicine Odds ratio Implantable cardioverter-defibrillator medicine.disease Defibrillators Implantable Ventricular Fibrillation Ventricular fibrillation Tachycardia Ventricular Cardiology Hydroxymethylglutaryl-CoA Reductase Inhibitors business Cohort study |
| Zdroj: | American Journal of Therapeutics. 19:261-268 |
| ISSN: | 1075-2765 |
| DOI: | 10.1097/mjt.0b013e3181f94c38 |
| Popis: | A few observational studies have shown the protective effect of statins on preventing ventricular tachycardia/ventricular fibrillation (VT/VF). However, the disparate study results prompt further exploration of this concept. We performed a meta-analysis to assess whether statin therapy is associated with a decrease in the incidence or recurrence of VT/VF in patients with an implantable cardioverter-defibrillator (ICD).The MEDLINE(®) and Cochrane databases were searched from 1980 to July 2009 for studies examining the effect of statins on VT/VF in recipients of ICDs. We retrieved all prospective cohort studies that examined this association. The endpoint was defined as appropriate ICD therapy for VT/VF. The quality of individual studies was assessed using the Newcastle Ottawa Scale.Seven prospective cohort studies met our inclusion criteria with a total of 2278 patients with a mean follow-up of 19.7 months. Pooled analysis of the eligible studies revealed that statin therapy was associated with a 45% reduction in the risk of developing VT/VF in recepients of ICDs [pooled odds ratio (pOR): 0.55; 95% confidence interval: 0.34-0.90; heterogeneity I(2) = 81%, P = 0.02]. In a subgroup analysis, the magnitude of the risk reduction in patients with ischemic cardiomyopathy was 54% (pOR: 0.46, P = 0.05). Sensitivity analysis including studies with higher methodological qualities alone showed a significant protective effect (pOR: 0.48, P = 0.01). There was no evidence of publication bias in the analysis.Our meta-analysis suggests an association between the use of statin and a reduction in the VT/VF occurrence in recipients of ICDs, mainly in patients with ischemic cardiomyopathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|